A pivotal study of litifilimab in cutaneous lupus erythematosus (CLE)
Latest Information Update: 19 Sep 2022
At a glance
- Drugs Litifilimab (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Registrational; Therapeutic Use
- Sponsors Biogen
- 19 Sep 2022 New trial record
- 16 Sep 2022 According to a Feinstein Institutes media release, the company plans to initiate this study later this year.